Canaccord lowered the firm’s price target on Doximity (DOCS) to $58 from $67 and keeps a Hold rating on the shares. The firm said they posted a strong beat and the previously implied 2H FY’26 guidance was essentially maintained which seemed to drive the shares lower. Canaccord said the conservative stance comes from potential DTC advertising and drug pricing changes that have the possibility to drive Pharma management to alter budgets in remaining months of calendar 2025 and plans for calendar 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity’s Earnings Call: Strong Growth and AI Focus
- Doximity price target lowered to $70 from $81 at Evercore ISI
- Balanced Outlook on Doximity: Strong Performance Meets Conservative Guidance
- Doximity Reports Strong Q2 Growth and AI Expansion
- Closing Bell Movers: Expedia up 15%, Affirm up 12% on earnings beats